YS-363

• Description :

  YS-363 is a potent, selective, and orally active EGFR inhibitor, with IC50s of 0.96 nM and 0.67 nM for wild-type and L858R mutant forms of EGFR, respectively. YS-363 can induce G0/G1 cell cycle arrest and apoptosis[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; EGFR

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ys-363.html

• Purity :

  99.52

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  COC1=C(OCCCN2CCOCC2)C=C3C(N=CN=C3C4=C(C5=CC=CC=C5)NC6=C4C=CC=C6)=C1

• Molecular Formula :

  C30H30N4O3

• Molecular Weight :

  494.58

• References & Citations :

  [1]He P, et, al. Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor. Biomed Pharmacother. 2023 Nov:167:115491.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  EGFR/ErbB1/HER1

• CAS Number :

  [2470908-90-6]